Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Farmers Insurance
Teva
McKesson
Moodys
Johnson and Johnson
Federal Trade Commission
Cipla
Accenture

Generated: April 22, 2018

DrugPatentWatch Database Preview

DOSTINEX Drug Profile

« Back to Dashboard

Which patents cover Dostinex, and when can generic versions of Dostinex launch?

Dostinex is a drug marketed by Pharmacia And Upjohn and is included in one NDA.

The generic ingredient in DOSTINEX is cabergoline. There are twelve drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the cabergoline profile page.
Drug patent expirations by year for DOSTINEX
Synonyms for DOSTINEX
(6aR,9R,10aR)-7-allyl-N-(3-(dimethylamino)propyl)-N-(ethylcarbamoyl)-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxamide
(8beta)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-(prop-2-en-1-yl)ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-prop-2-en-1-ylergoline-8-carboxamide
(8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide
1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea
1-[(6-Allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)-propyl]-3-ethylurea
1-[(6-allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea
1-[3-(dimethylamino)propyl]-3-ethyl-1-[(2R,4R,7R)-6-(prop-2-en-1-yl)-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),9,12,14-tetraene-4-carbonyl]urea
1-[3-(DIMETHYLAMINO)PROPYL]-3-ETHYL-1-[(2R,4R,7R)-6-(PROP-2-EN-1-YL)-6,11-DIAZATETRACYCLO[7.6.1.0(2),?.0(1)(2),(1)?]HEXADECA-1(15),9,12(16),13-TETRAENE-4-CARBONYL]UREA
1-[3-(dimethylamino)propyl]-3-ethyl-1-{[(2R,4R,7R)-6-(prop-2-en-1-yl)-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),9,12,14-tetraen-4-yl]carbonyl}urea
1-[3-(dimethylamino)propyl]-3-ethyl-1-{[(2R,4R,7R)-6-(prop-2-en-1-yl)-6,11-diazatetracyclo[7.6.1.0;{2,7}.0;{12,16}]hexadeca-1(16),9,12,14-tetraen-4-yl]carbonyl}urea
1-ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate
1-Ethyl-3-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'beta-carbonyl)urea
1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea
409C907
6-allyl-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-ergoline-8beta-carboxamide
81409-90-7
85329-89-1 (diphosphate)
AB01275484-01
AC-26126
AC1L1HO0
AC1Q5OQ0
AKOS015961587
AN-36255
BC207368
BDBM50426497
BIDD:GT0775
BRD-K86882815-001-01-6
BRN 6020775
C08187
C26H37N5O2
Cabaser
Cabaser (TN)
Cabaseril
Cabergolina
Cabergolina [Spanish]
cabergoline
Cabergoline (JAN/USAN/INN)
Cabergoline [USAN:BAN:INN]
Cabergoline, >=98% (HPLC)
Cabergoline, European Pharmacopoeia (EP) Reference Standard
Cabergoline, United States Pharmacopeia (USP) Reference Standard
Cabergolinum
Cabergolinum [Latin]
Caberlin
CAS-81409-90-7
CG-101
CHEBI:3286
CHEMBL1201087
CTK8F8406
D00987
D04EGX
DB00248
Dostinex (TN)
DR002797
DSSTox_CID_2719
DSSTox_GSID_22719
DSSTox_RID_76698
DTXSID6022719
Ergoline-8-carboxamide, N-(3-(dimethylamino)propyl)-N-((ethylamino)carbonyl)-6-(2-propenyl)-, (8-beta)-
Ergoline-8beta-carboxamide, N-(3-(dimethylamino)propyl)-N-((ethylamino)carbonyl)-6-(2-propenyl)-
FCE-21336
FT-0081285
FT-0650562
Galastop
GTPL37
HMS2090A09
K450
KORNTPPJEAJQIU-KJXAQDMKSA-N
LL60K9J05T
LS-64370
MFCD00867887
MolPort-003-845-557
N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-allyl-ergoline-8beta-carboxamide
NCGC00167821-01
NCGC00344544-01
PL070592
SC-19831
SCHEMBL42292
Sogilen
SR-05000001493
SR-05000001493-2
Tox21_112589
Tox21_112589_1
UNII-LL60K9J05T
ZINC3800008

US Patents and Regulatory Information for DOSTINEX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmacia And Upjohn DOSTINEX cabergoline TABLET;ORAL 020664-001 Dec 23, 1996 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Johnson and Johnson
AstraZeneca
Accenture
Harvard Business School
Julphar
Chinese Patent Office
Chubb
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.